UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SEC FILE NUMBER
FORM 12B-25
NOTIFICATION OF LATE FILING SEC FILING NO. 0-17602
(Check one): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K
[ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR
For Period Ended: December 31, 2004
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended: ____________________________
--------------------------------------------------------------------------------
Read Instruction (on page 3) Before Preparing Form. Please Print or Type.
--------------------------------------------------------------------------------
Nothing in this form shall be construed to imply that the Commission
has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
--------------------------------------------------------------------------------
PART I - REGISTRANT INFORMATION
--------------------------------------------------------------------------------
Full Name of Registrant
GenoMed, Inc.
--------------------------------------------------------------------------------
Former Name if Applicable
--------------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)
9666 Olive Boulevard, Suite 310
--------------------------------------------------------------------------------
City, State and Zip Code
St. Louis, Missouri 63132
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
PART II - RULES 12b-25(b) AND (c)
--------------------------------------------------------------------------------
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)
((a) The reasons described in detail in Part III of this form could not be
( eliminated without unreasonable effort or expense;
(
((b) The subject annual report, semi-annual report, transition report on
( Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion
( thereof, will be filed on or before the fifteenth calendar day
( following the prescribed due date; or the subject quarterly report or
( transition report on Form 10-Q or subject distribution report on Form
( 10-D, or portion thereof will be filed on or before the fifth calendar
( day following the prescribed due date; and
(
((c) The accountant's statement or other exhibit required by Rule 12b-25(c)
( has been attached if applicable.
--------------------------------------------------------------------------------
PART III - NARRATIVE
--------------------------------------------------------------------------------
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR,
or the transition report or portion thereof, could not be filed within the
prescribed time period.
-------------------------------------------
The Form 10-K could not be filed within the prescribed time period because the
registrant had not been able to complete required Financial Statements for the
year ended December 31, 2004 in a timely manner.
--------------------------------------------------------------------------------
PART IV - OTHER INFORMATION
--------------------------------------------------------------------------------
(1) Name and telephone number of person to contact in regard to this
notification:
Karen Jordan (314) 259-5840
------------------- --- --------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If answer is no,
identify report(s). [X] Yes [ ] No
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion hereof?
[ ] Yes [X] No
If so, attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
GenoMed, Inc.
------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: April 1, 2005 By: /s/ David Moskowitz
-------------------------------------- ---------------------------
David Moskowitz
Chief Executive Officer
INSTRUCTION: The form may be signed by an executive officer of the
registrant or by any other fully authorized representative. The name and
title of the person signing the form shall be typed or printed beneath the
signature. If the statement is signed on behalf of the registrant by an
authorized representative (other than an executive officer), evidence of
the representative's authority to sign on behalf of the registrant shall be
filed with the form.